CClinicalTrials.gg
Sign In
CompletedNCT03258593Updated Aug 25, 2026Results posted

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

A Phase 1 interventional study of Durvalumab and Vicineum in Urinary Bladder Neoplasms, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background:

Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicineum and Durvalumab may help the immune system find and destroy cancer cells.

Objective:

To test if the drugs Durvalumab and Vicineum together are safe and effective to treat people with bladder cancer that has not spread to the muscle in the bladder.

Eligibility:

People ages 18 and older who have bladder cancer that has not spread to the muscle in the bladder and was treated unsuccessfully with Bacillus Calmette-Guerin

Design:

Participants will be screened with:

Medical history

Physical exam

Blood and urine tests

Tumor sample from previous surgery. If one is not available, they will have a biopsy: A small piece of tumor is removed.

Cystoscopy to examine the inside of the bladder. This may include a biopsy or removing tumors.

Computed tomography (CT) or magnetic resonance imaging (MRI): They lie in a machine that takes pictures of the body.

Electrocardiogram to test heart function

Participants will receive Durvalumab and Vicineum in 2 phases:

First phase: Durvalumab every 4 weeks and Vicineum once a week for 3 months

Second phase: Durvalumab every 4 weeks and Vicineum once every other week

Participants will have tumor samples taken every 3 months. They will have blood and urine tests throughout the study.

Participants will continue treatment for up to 2 years.

Participants will have a visit about 30 days after their last treatment. This includes blood and urine tests. It may include a cytoscopy or additional biopsies.

Read the detailed description

In 2016, it is estimated that there will be 76,960 new cases of bladder cancer and 16,390 deaths associated with bladder cancer. Bladder cancer is associated with the highest costs among all types of cancer, due to the need for lifelong routine monitoring and treatment. Approximately 70% of cases are non-muscle invasive bladder cancer (NMIBC) at presentation and are treated by transurethral resection of bladder tumor (TURBT) followed by intravesical treatment with BCG (Bacillus Calmette-Guerin) or mitomycin C. However, in the setting of high-grade disease, these therapies can become ineffective over time in up to two-thirds of patients and disease progression to muscle invasive bladder cancer (MIBC) can occur. In patients who present with CIS (carcinoma in situ) rates of progression are greater than 50%. Progression to MIBC portends a poor outcome as only 50% of patients will survive five years despite undergoing radical cystectomy. Clearly, there is a large unmet need in therapeutic options for NMIBC that recurs or progresses.

Vicineum(TM) is a recombinant fusion protein, VB4-845, that contains a humanized single-chain antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) antigen linked to ETA (252-608), a truncated form of Pseudomonas exotoxin A (ETA). EpCAM is overexpressed on the surface of urothelial carcinoma cells and therefore represents a good target for Vicineum(TM) to bind to. In a previous phase II study in BCG refractory or BCG intolerant patients with high grade bladder cancer, 16% of patients treated with induction and maintenance therapy with Vicineum(TM) remained disease-free at 1 year. As a result, Vicineum(TM) is currently being evaluated as a single agent in a phase III trial.

Pre-clinical work with a drug called Proxinium, an earlier version of Vicineum(TM), demonstrated an abscopal effect and synergy with the use of a checkpoint blockade inhibitor. Although it was done in a non-small cell lung cancer (NSCLC) model, the results were impressive in causing tumor shrinkage. Durvalumab is a human monoclonal antibody (MAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) (B7 homolog 1 [B7-H1], cluster of differentiation [CD]274) to programmed cell death 1 (PD-1; CD279) and CD80 (B7-1). Durvalumab has been demonstrated to have activity against advanced metastatic urothelial bladder cancer whose tumor has progressed during or after one standard platinum-based regimen in a phase I trial.

Therefore, this trial will take two agents with single agent activity against urothelial cancer and combine them in a Phase I trial for patients with high-grade NMIBC Previously Treated with BCG.

Objectives:

Primary Objectives:

To evaluate the safety and tolerability of durvalumab and Vicineum when administered in combination to subjects with BCG-refractory high-grade NMIBC

Eligibility:

Subjects must have a histologically confirmed high-grade non-muscle invasive urothelial carcinoma (transitional cell carcinoma) of the bladder as follows:

Carcinoma-in-situ (CIS) with or without papillary tumors

High-grade Ta or T1 disease based on a biopsy/TURBT performed within 12 weeks of the initial dose of study treatment. If multiple bladder biopsies/TURBTs are required to confirm eligibility, the timing of the last bladder biopsy to the initial dose of study treatment must be within 12 weeks.

Subjects with BCG unresponsive disease as defined by the Society of Urologic Oncology and the Food and Drug Administration (FDA): Subjects must have received at least two courses of intravesical BCG (at least 5 of 6 induction doses of BCG and at least 2 of 3 maintenance doses of BCG under a maintenance regimen or at least 2 doses of a repeat induction course). See exception below for persistent T1 disease below. There is no upper limit on the amount of prior BCG a subject may have received.

Patients with persistent T1 high grade disease on TURBT following a single induction course of BCG (at least 5 of 6 doses) may also be eligible for this trial provided that the patient is surgically unfit for cystectomy as deemed by the investigator or the patient declines cystectomy

Design:

This is a Phase I, open-label study of the combination of durvalumab and Vicineum in subjects with high-grade NMIBC previously treated with BCG.

All subjects will receive Vicineum intravesically and durvalumab systemically at the standard doses for both drugs as determined by Phase II trials for each drug, as no synergy or additive effect is expected for adverse events.

Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.

Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that patient is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.

Vicineum will be given as monotherapy for 1 week followed by treatment with the combination of Vicineum and durvalumab starting week 2.

In the initial six patients, three subjects at a time will enroll at these doses and schedules. Dose-liming toxicity (DLT) for each subject will be determined during the initial 6-week period that the subject is on treatment (i.e., the DLT period). When all subjects in the initial cohort have been on treatment through the DLT period, all available safety data will be considered in decisions to enroll additional subjects at this dose level, or to de-escalate the dose(s) of study drug(s), based on a standard "3 + 3" design. There will be no dose-escalations in this study. The dose of durvalumab will remain at 1500 mg every 4 weeks, and the dose of each intravesical Vicineum treatment can be reduced to 20 mg if the initial doses in combination induce DLTs.

After the first six patients, an additional 18 subjects will be enrolled at the initial doses or at the reduced doses (if DLTs resulted in the first 6 patients) in order to obtain additional safety data, biomarker data and preliminary anti-tumor activity.

Each subject's course will consist of the following periods:

Screening/Baseline Period: The subject is consented and undergoes screening assessments to determine eligibility for the study.

Treatment Period: The subject is treated and monitored for safety. Biomarker data will be obtained prior to treatment and at periodic intervals during treatment. Subjects who remain free of high-grade NMIBC after 12 months of study treatment may continue to receive treatment for an additional 12 months until they develop recurrent high-grade disease, disease progression, or intolerable toxicity, or meet another withdrawal criterion (e.g., consent withdrawal, pregnancy).

Post-Treatment. The subject will return to the study site monthly for up to 90 days after the last dose of immunotherapy for end-of-treatment assessments. Subjects with ongoing clinically significant related adverse events (AEs) or serious adverse events (SAEs) will have additional follow-up after the initial post-treatment visit.

02

Conditions studied

  • Urinary Bladder Neoplasms

Keywords

  • Carcinoma-in-situ
  • High-grade Ta or T1 disease
  • Papillary Tumors
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients must have histologically or cytologically confirmed by National Cancer Institute (NCI) Laboratory of Pathology as high-grade non-muscle invasive urothelial (transitional cell carcinoma) of the bladder as follows:

    • Carcinoma-in-situ (CIS) with or without papillary tumors
    • High-grade Ta or T1 disease based on a biopsy/transurethral resection of bladder tumor (TURBT) performed within 12 weeks of the initial dose of study treatment. If multiple bladder biopsies/TURBTs are required to confirm eligibility, the timing of the last bladder biopsy to the initial dose of study treatment must be within 12 weeks.
    • Patients with persistent T1 high grade disease on TURBT following a single induction course of BCG (Bacillus Calmette-Guerin) (at least 5 of 6 doses) may also be eligible for this trial provided that the patient is surgically unfit for cystectomy as deemed by the investigator or the patient declines cystectomy.
  • Subjects with BCG unresponsive disease as defined by the Society of Urologic Oncology and the Food and Drug Administration (FDA): Subjects must have received at least two courses of intravesical BCG (at least 5 of 6 induction doses of BCG and at least 2 of 3 maintenance doses of BCG under a maintenance regimen or at least 2 doses of a repeat induction course). Please note exception above for persistent T1 disease. There is no upper limit on the amount of prior BCG a subject may have received.
  • Patients who have met eligibility criterion above must have received last BCG dose within a year of enrollment.
  • The investigator must document that he/she believes the subject would not benefit from additional BCG treatment at the time of study entry.
  • Age >= 18 years at time of signing the informed consent form (ICF). Because no dosing or adverse event data are currently available on the use of Vicineum in combination with durvalumab in patients \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials. Furthermore, non-muscle invasive bladder cancer (NMIBC) does not occur in children.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

  • Adequate organ and marrow function as defined below:

    • Hemoglobin >= 9.0 g/dL
    • Absolute neutrophil count (ANC) >= 1.5 x 10\^9/L (> 1500 per mm\^3)
    • Platelet count >= 75 x 10\^9/L (>75,000 per mm\^3)
    • Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN).
    • Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamate-pyruvate transaminase (SGPT) less than or equal to 2.5 x institutional ULN

    • Creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:

      • Males: Creatinine CL (mL/min) = (Weight (kg) x (140 - Age))/72 x serum creatinine (mg/dL)
      • Females: Creatinine CL (mL/min) = (Weight (kg) x (140 - Age) x 0.85)/72 x serum creatinine (mg/dL)

  • Female subjects must either be of non-reproductive potential (i.e., post-menopausal as described below) OR history of surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

    • Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
    • Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, or had chemotherapy-induced menopause with last menses >1 year ago
  • The effects of Vicineum and durvalumab on the developing human fetus are unknown. For this reason, all sexually active subjects agree to use barrier contraception (i.e., condoms) while receiving study treatment and for 120 days following their last dose of study treatment. Female subjects of child-bearing potential and male subjects whose sexual partners are women of childbearing potential (WOCBP) agree to use barrier contraception and a second form of contraception while receiving study treatment and for 4 months following their last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Written informed consent obtained from the subject prior to performing any protocol- related procedures
  • Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  • Body weight > 30 kg

Exclusion criteria

EXCLUSION CRITERIA:

  • Patients who are receiving any other investigational agents.
  • QT interval corrected for heart rate using Fridericia's formula the corrected QT interval by Fridericia (QTcF) >=470 ms. (Any clinically significant abnormalities detected require triplicate ECG results and a mean QT interval corrected for heart rate using Fridericia's formula (QTcF) >=470 ms calculated from 3 ECGs.)
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Vicineum or durvalumab or other agents used in the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Urinary tract infections (UTIs) are excluded from being an exclusion criterion for treatment unless they are grade 3 or higher.
  • Pregnant women are excluded from this study because it is unknown whether Vicineum and/or durvalumab have any teratogenic effects. In nursing mothers, breastfeeding should be discontinued as these medications may have the potential risk for adverse events in nursing infants secondary to treatment of the mother.
  • Any previous treatment with a programmed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, including durvalumab
  • Evidence of non-bladder urothelial (transitional cell) carcinoma by biopsy, cytology, or radiological imaging within the past 2 years of treatment (e.g., upper tract transitional cell carcinoma, urethral urothelial carcinoma).
  • Subjects with hydronephrosis, except for those subjects where hydronephrosis has been longstanding (i.e., predates the diagnosis of the CIS (carcinoma in situ), Ta, or T1 by more than 2 years) and diagnostic evaluation at screening shows no evidence of tumor causing the hydronephrosis.
  • Any other anticancer therapy (e.g., chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy, investigational agent) within 28 days of the first dose of study therapy (and within 6 weeks for nitrosourea or mitomycin C) other than a single dose of intravesical chemotherapy which is permitted between 28 days and 14 days prior to the first dose of study treatment.
  • The subject has a diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancer, localized prostate cancer on active surveillance, or localized solid tumors deemed cured by surgery and not treated with systemic anticancer therapy and not expected to require anticancer therapy in the next 2 years i.e., while the subject may be taking study treatment.
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.

  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Grave's disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:

    • Subjects with vitiligo or alopecia
    • Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormonal replacement
    • Any chronic skin condition that does not require systemic therapy
    • Subjects without active disease in the last 5 years may be included but only after consultation with the Principal Investigator
    • Subjects with celiac disease controlled by diet alone
  • History of primary immunodeficiency.
  • History of allogeneic organ transplant.
  • History of hypersensitivity to durvalumab or any excipient
  • History of hypersensitivity to Vicineum or its components
  • Active infection with tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and purified protein derivative (PPD) testing if indicated), hepatitis B (known positive HBV surface antigen (HBsAg) result, hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with HIV are excluded from participating on this clinical trial because their immunodeficiency would confound the evaluation of adverse events which would hinder meeting the primary objective. Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).
  • History of leptomeningeal carcinomatosis
  • Receipt of live attenuated vaccination within 30 days prior to the first dose of Vicineum or durvalumab
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
  • Subjects with uncontrolled seizures

  • Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade >=2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria

    • Subjects with Grade >=2 neuropathy will be evaluated on a case-by-case basis after consultation with the Principal Investigator.
    • Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Principal Investigator.
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg

    Durvalumab + Vicineum, escalating doses. Up to 2 dose levels will be evaluated in the first 6 - 12 participants.

    Drug: Durvalumab · Drug: Vicineum · Drug: Acetaminophen · Drug: Antihistamine · Procedure: Bladder Biopsy · Procedure: TURBT · Procedure: Cystoscopy · Diagnostic Test: Urine cytology · Diagnostic Test: Electrocardiogram · Diagnostic Test: CT · Diagnostic Test: MRI

  • Experimental
    Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg

    Durvalumab + Vicineum, at the maximum tolerated dose (MTD). Up to 24 participants.

    Drug: Durvalumab · Drug: Vicineum · Drug: Acetaminophen · Drug: Antihistamine · Procedure: Bladder Biopsy · Procedure: TURBT · Procedure: Cystoscopy · Diagnostic Test: Urine cytology · Diagnostic Test: Electrocardiogram · Diagnostic Test: CT · Diagnostic Test: MRI

  • Experimental
    Level 1, Durvalumab 1500mg intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg

    Level 1, Durvalumab 1500mg intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mg

    Drug: Durvalumab · Drug: Vicineum · Drug: Acetaminophen · Drug: Antihistamine · Procedure: Bladder Biopsy · Procedure: TURBT · Procedure: Cystoscopy · Diagnostic Test: Urine cytology · Diagnostic Test: Electrocardiogram · Diagnostic Test: CT · Diagnostic Test: MRI

  • Experimental
    Arm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)

    Arm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)

    Drug: Durvalumab · Drug: Vicineum · Drug: Acetaminophen · Drug: Antihistamine · Procedure: Bladder Biopsy · Procedure: TURBT · Procedure: Cystoscopy · Diagnostic Test: Urine cytology · Diagnostic Test: Electrocardiogram · Diagnostic Test: CT · Diagnostic Test: MRI

Interventions

  • DrugDurvalumab

    Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.

    Also known as: Imfinzi

  • DrugVicineum

    Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.

  • DrugAcetaminophen

    Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.

    Also known as: Tylenol, Panadol, Paracetamol

  • DrugAntihistamine

    Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.

    Also known as: Diphenhydramine

  • ProcedureBladder Biopsy

    Bladder biopsy at screening and every 3 months before each cystoscopy per schema.

  • ProcedureTURBT

    Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.

    Also known as: Transurethral resection of a bladder tumor

  • ProcedureCystoscopy

    Urine cytology at screening and every 3 months before each cystoscopy per schema.

  • Diagnostic testUrine cytology

    Urine cytology at baseline and every 3 months before each cystoscopy per schema.

  • Diagnostic testElectrocardiogram

    Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.

    Also known as: ECG

  • Diagnostic testCT

    Computed tomography (CT) at screening and every 12 months while on study.

    Also known as: Computed tomography

  • Diagnostic testMRI

    Magnetic resonance imaging (MRI) at screening and every 12 months while on study.

    Also known as: Magnetic resonance imaging

05

What researchers measure

Primary outcomes

  1. Number of Grades 1-5 Adverse Events

    Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild, grade 2 is moderate, grade 3 is severe, grade 4 is life-threatening, and grade 5 is death related to adverse event.

    Time frame: Through study completion, an average of 315 days

Secondary outcomes

  1. Urinary Epithelial Cell Adhesion Molecule (EpCAM) Compared Between Participants Who Have a Clinical Response to Therapy vs. Those Who Do Not Respond

    Urinary EpCAM will be measured and will be compared between participants who have a clinical response to therapy vs. those who do not respond. Although it is expected to have low power, a comparison of the EpCAM levels may be compared between the two response categories using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

    Time frame: Baseline, week 1, weeks 2-5, week 6, week 10, week 12

  2. Response Rate

    The response to treatment will be determined for evaluable participants who receive treatment and was measured as follows: Recurrence is suspected and/or determined by urine cytology and/or cystoscopic exam and then confirmed pathologically after a transurethral resection of bladder tumor (TURBT). Complete response rate for carcinoma in situ (CIS) is defined as the absence of CIS upon follow-up biopsies. Disease progression is defined as upstaging from a lower stage to a higher stage (e.g., Ta to T1-T4 or T1 to T2-4; CIS to T1 or CIS to T2-T4; or any N+ or M+ in these high-grade tumors).

    Time frame: From enrollment until event occurrence (recurrence, progression); twelve weeks.

  3. Pharmacokinetic Parameters in Urine Maximum Concentration (Cmax) of Vicineum

    Evaluate the pharmacokinetic parameters of Vicineum obtained by urine samples. Urinary Vicineum (in ng/mL).

    Time frame: Baseline, week 1, week 6, week 12

  4. Change in Programmed Death-ligand 1 (PD-L1) Levels Between Responders and Non-Responders

    PD-L1 levels will be obtained at baseline and after treatment with both agents. The change in levels will be determined between the two measurements, and these changes will be compared between responders and non-responders. Although it is expected to have low power, in each case the comparisons between the two response categories will be made using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

    Time frame: Baseline and after treatment with both agents, from enrollment up to 5 weeks

  5. Change in Programmed Cell Death Protein 1 (PD-1) Levels Between Responders and Non-Responders

    Programmed Cell Death Protein 1 (PD-1) levels will be obtained at baseline and after treatment with both agents. The change in levels will be determined between the two measurements, and these changes will be compared between responders and non-responders. Although it is expected to have low power, in each case the comparisons between the two response categories will be made using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

    Time frame: baseline and after treatment with both agents

  6. Change in Programmed Death-ligand 1 (PD-L1) Levels Between Participants Who Respond and Have Stable Disease (SD), and Those With Progressive Disease (PD)

    PD-L1 levels will be obtained at baseline and after treatment with both agents. The change will be compared between those who respond or have stable disease (SD (clinical benefit=Complete Response (CR)+Partial Response (PR)+SD) and those with progressive disease (PD). Although it is expected to have low power, in each case the comparisons between the two response categories will be made using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

    Time frame: Baseline and after treatment, from enrollment up to 5 weeks

  7. Change in Programmed Cell Death Protein 1(PD-1) Levels Between Participants Who Respond and Have Stable Disease (SD), and Those With Progressive Disease (PD)

    PD-1 levels will be obtained at baseline and after treatment with both agents. The change will be compared between those who respond or have stable disease (SD (clinical benefit=Complete Response (CR)+Partial Response (PR)+SD) and those with progressive disease (PD). Although it is expected to have low power, in each case the comparisons between the two response categories will be made using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

    Time frame: baseline and after treatment

  8. Changes in the Immune Parameters Obtained From Blood Samples

    All evaluable participants will have determinations of many immune parameters at baseline, 3 months, and 6 months. The changes in the parameters obtained from blood samples will be determined at baseline vs. 3 months, and baseline vs. 6 months. Comparisons of the paired values will be performed using a Wilcoxon signed rank test, and a Hochberg adjustment may be used.

    Time frame: baseline, 3 weeks, and 5 weeks

  9. Changes in the Immune Parameters Obtained From Biopsies

    All evaluable participants will have determinations of many immune parameters at baseline, 3 months, and 6 months. The changes in the parameters obtained from biopsies will be obtained from baseline vs. a single second biopsy at 6 months. Comparisons of the paired values will be performed using a Wilcoxon signed rank test, and a Hochberg adjustment may be used.

    Time frame: baseline, 3 months, and 6 months

  10. Disease Free Survival (DFS)

    A DFS curve will be created using the Kaplan-Meier method based on all participants considered to be evaluable based on having received protocol treatment. DFS survival is defined as the time from the start of treatment until disease recurrence or death. Recurrence is suspected and/or determined by urine cytology and/or cystoscopic exam and then confirmed pathologically after a bladder biopsy or transurethral resection of bladder tumor (TURBT).

    Time frame: Assessed from start of therapy to disease recurrence or last follow up; up to 1 year.

Other outcomes

  1. Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

    Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: Through study completion, an average of 315 days.

  2. Maximum Tolerated Dose (MTD) of Durvalumab

    The MTD will be identified based on being the dose level at which 0 or 1 participants in 6 has a dose-limiting toxicity (DLT). A DLT will be defined as any Grade 3 or higher toxicity that occurs during the initial 6-week period the subject is on treatment (i.e., the DLT evaluation period). Grade 3 is severe, grade 4 is life-threatening and grade 5 is death related to adverse event.

    Time frame: 6 weeks

  3. Maximum Tolerated Dose (MTD) of Vicineum

    The MTD will be identified based on being the dose level at which 0 or 1 participants in 6 has a dose-limiting toxicity (DLT). A DLT will be defined as any Grade 3 or higher toxicity that occurs during the initial 6-week period the subject is on treatment (i.e., the DLT evaluation period). Grade 3 is severe, grade 4 is life-threatening and grade 5 is death related to adverse event.

    Time frame: 6 weeks

  4. Dose-Limiting Toxicity (DLT)

    A DLT will be defined as any Grade 3 or higher toxicity that occurs during the initial 6-week period the subject is on treatment (i.e., the DLT evaluation period). Grade 3 is severe, grade 4 is life-threatening and grade 5 is death related to adverse event.

    Time frame: 6 weeks

06

Results

Posted Oct 26, 2023

Participant flow

Run-In Induction Phase
Participant flow — Run-In Induction Phase
MilestoneRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mgArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)
Started12000
Completed12000
Not completed0000
Run-In Maintenance Phase
Participant flow — Run-In Maintenance Phase
MilestoneRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mgArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)
Started12000
Completed5000
Not completed7000
Withdrew: Disease recurrence4000
Withdrew: Disease progression3000
Expansion Induction Phase
Participant flow — Expansion Induction Phase
MilestoneRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mgArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)
Started0300
Completed0300
Not completed0000
Expansion Maintenance Phase
Participant flow — Expansion Maintenance Phase
MilestoneRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgLevel 1, Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 20 mgArm 2, Durvalumab + Vicineum at the Maximum Tolerated Dose (MTD)
Started0300
Completed0100
Not completed0200
Withdrew: Withdrawal by subject0100
Withdrew: Physician decision0100

Outcome measures

PrimaryNumber of Grades 1-5 Adverse Events

Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild, grade 2 is moderate, grade 3 is severe, grade 4 is life-threatening, and grade 5 is death related to adverse event.

Time frame:
Through study completion, an average of 315 days
Reported as:
Number · adverse events
Number of Grades 1-5 Adverse Events
adverse eventsRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
Grade 112315
Grade 29312
Grade 3404
Grade 4000
Grade 5000
SecondaryUrinary Epithelial Cell Adhesion Molecule (EpCAM) Compared Between Participants Who Have a Clinical Response to Therapy vs. Those Who Do Not Respond

Urinary EpCAM will be measured and will be compared between participants who have a clinical response to therapy vs. those who do not respond. Although it is expected to have low power, a comparison of the EpCAM levels may be compared between the two response categories using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

Time frame:
Baseline, week 1, weeks 2-5, week 6, week 10, week 12

Results for this outcome have not been posted.

SecondaryResponse Rate

The response to treatment will be determined for evaluable participants who receive treatment and was measured as follows: Recurrence is suspected and/or determined by urine cytology and/or cystoscopic exam and then confirmed pathologically after a transurethral resection of bladder tumor (TURBT). Complete response rate for carcinoma in situ (CIS) is defined as the absence of CIS upon follow-up biopsies. Disease progression is defined as upstaging from a lower stage to a higher stage (e.g., Ta to T1-T4 or T1 to T2-4; CIS to T1 or CIS to T2-T4; or any N+ or M+ in these high-grade tumors).

Time frame:
From enrollment until event occurrence (recurrence, progression); twelve weeks.
Reported as:
Number · percentage of participants
Response Rate
percentage of participantsRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
Complete response41.666.646.6
Recurrence58.333.353.3
Disease progression2533.326.6
SecondaryPharmacokinetic Parameters in Urine Maximum Concentration (Cmax) of Vicineum

Evaluate the pharmacokinetic parameters of Vicineum obtained by urine samples. Urinary Vicineum (in ng/mL).

Time frame:
Baseline, week 1, week 6, week 12
Reported as:
Median · ng/mL
Pharmacokinetic Parameters in Urine Maximum Concentration (Cmax) of Vicineum
ng/mLRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
Baseline2.5 (1.5 to 3.8)1.5 (1.5 to 1.5)3.2 (2.1 to 7.4)
Week 1, Day 14320.0 (10.6 to 11965.5)305.4 (195.8 to 15231.8)3738.7 (49.9 to 14072.6)
Week 12.6 (1.7 to 5.5)1.5 (1.5 to 1.5)4.7 (2.1 to 6.5)
Week 63.2 (1.5 to 4.7)1.5 (1.5 to 1.5)4.3 (2.4 to 7.5)
Week 123.5 (1.8 to 5.5)7.5 (7.5 to 7.5)4.8 (2.1 to 7.5)
SecondaryChange in Programmed Death-ligand 1 (PD-L1) Levels Between Responders and Non-Responders

PD-L1 levels will be obtained at baseline and after treatment with both agents. The change in levels will be determined between the two measurements, and these changes will be compared between responders and non-responders. Although it is expected to have low power, in each case the comparisons between the two response categories will be made using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

Time frame:
Baseline and after treatment with both agents, from enrollment up to 5 weeks
Reported as:
Median · pg/mL
Change in Programmed Death-ligand 1 (PD-L1) Levels Between Responders and Non-Responders
pg/mLRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
Responders PDL1 levels after treatment (vs baseline573.4 (533.8 to 670.3)342.5 (319.4 to 365.6)533.8 (443.5 to 621.8)
Non-responders PDL1 levels after treatment (vs baseline)505.9 (421.3 to 532.4)228.4 (228.4 to 228.4)489.7 (368.6 to 524.2)
Statistical analysis
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Wilcoxon Rank sum test · p = 0.202 (Unadjusted p-value) · Median difference (net): 67.5 · 95% CI 25 to 75
  • Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Wilcoxon Rank sum test · p = 0.667 (Unadjusted p-value) · Median difference (net): 114 · 95% CI 67.9 to 160.3
  • Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Wilcoxon Rank sum test · p = 0.463 · Median difference (net): 44.1 · 95% CI 25 to 75
SecondaryChange in Programmed Cell Death Protein 1 (PD-1) Levels Between Responders and Non-Responders

Programmed Cell Death Protein 1 (PD-1) levels will be obtained at baseline and after treatment with both agents. The change in levels will be determined between the two measurements, and these changes will be compared between responders and non-responders. Although it is expected to have low power, in each case the comparisons between the two response categories will be made using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

Time frame:
baseline and after treatment with both agents

Results for this outcome have not been posted.

SecondaryChange in Programmed Death-ligand 1 (PD-L1) Levels Between Participants Who Respond and Have Stable Disease (SD), and Those With Progressive Disease (PD)

PD-L1 levels will be obtained at baseline and after treatment with both agents. The change will be compared between those who respond or have stable disease (SD (clinical benefit=Complete Response (CR)+Partial Response (PR)+SD) and those with progressive disease (PD). Although it is expected to have low power, in each case the comparisons between the two response categories will be made using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

Time frame:
Baseline and after treatment, from enrollment up to 5 weeks
Reported as:
Median · pg/mL
Change in Programmed Death-ligand 1 (PD-L1) Levels Between Participants Who Respond and Have Stable Disease (SD), and Those With Progressive Disease (PD)
pg/mLRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
PDL1 level changes in participants with SD (treatment vs baseline)533.8 (498.3 to 573.4)342.5 (319.4 to 365.6)505.9 (378.9 to 561.0)
PDL1 level changes in participants with PD (treatment vs baseline516 (494.8 to 612.9)228.4 (228.4 to 228.4)494.8 (412.2 to 564.6)
Statistical analysis
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Wilcoxon Rank sum test · p = 0.863 · Median difference (net): -17.75 · 95% CI -211.6 to 170.3Median change; Signed Rank (S/R) of post-treatment PDL-1 levels minus baseline.
  • Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Wilcoxon Rank sum test · p = 0.666 · Median difference (net): 114.1 · 95% CI 67.9 to 160.3Median change; Signed Rank (S/R) of post-treatment PDL-1 levels minus baseline.
  • Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Wilcoxon Rank sum test · p = 0.949 · Median difference (net): 21.3 · 95% CI -203.9 to 269.9Median change; Signed Rank (S/R) of post-treatment PDL-1 levels minus baseline.
SecondaryChange in Programmed Cell Death Protein 1(PD-1) Levels Between Participants Who Respond and Have Stable Disease (SD), and Those With Progressive Disease (PD)

PD-1 levels will be obtained at baseline and after treatment with both agents. The change will be compared between those who respond or have stable disease (SD (clinical benefit=Complete Response (CR)+Partial Response (PR)+SD) and those with progressive disease (PD). Although it is expected to have low power, in each case the comparisons between the two response categories will be made using a Wilcoxon rank sum test, with the resulting p-value intended to help describe the differences noted.

Time frame:
baseline and after treatment

Results for this outcome have not been posted.

SecondaryChanges in the Immune Parameters Obtained From Blood Samples

All evaluable participants will have determinations of many immune parameters at baseline, 3 months, and 6 months. The changes in the parameters obtained from blood samples will be determined at baseline vs. 3 months, and baseline vs. 6 months. Comparisons of the paired values will be performed using a Wilcoxon signed rank test, and a Hochberg adjustment may be used.

Time frame:
baseline, 3 weeks, and 5 weeks
Reported as:
Median · pg/mL
Changes in the Immune Parameters Obtained From Blood Samples
pg/mLRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
3 weeks Interferon Gamma (IFN-γ) vs Baseline4.340 (0.950 to 9.315)0.640 (-0.035 to 2.225)3.850 (0.720 to 6.525)
5 weeks Interferon Gamma (IFN-γ) vs Baseline3.290 (1.375 to 8.312)1.750 (0.985 to 12.265)3.120 (1.370 to 10.825)
3 weeks Interleukin 6 (IL-6) vs Baseline0.395 (0.037 to 0.802)0.180 (0.115 to 0.320)0.280 (0.050 to 0.590)
5 weeks Interleukin 6 (IL-6) vs Baseline0.540 (-0.070 to 0.870)0.220 (0.145 to 0.520)0.400 (0.005 to 0.770)
3 weeks Interleukin 8 (IL-8) vs Baseline0.730 (-0.482 to 1.370)0.880 (-0.795 to 10.295)0.860 (-0.895 to 1.610)
5 weeks Interleukin 8 (IL-8) vs Baseline-0.395 (-0.647 to 0.597)-0.160 (-0.455 to 10.145)-0.180 (-0.665 to 0.715)
3 weeks Interleukin 10 (IL-10) vs Baseline0.120 (0.047 to 0.202)0.07 (-0.04 to 0.15)0.120 (0.045 to 0.205)
5 weeks Interleukin 10 (IL-10) vs Baseline0.105 (0.047 to 0.365)0.120 (0.075 to 0.305)0.120 (0.045 to 0.380)
3 weeks Tumor Necrosis Factor Alpha (TNF-α) vs Baseline0.400 (0.207 to 0.560)0.260 (0.100 to 0.525)0.350 (0.165 to 0.590)
5 weeks Tumor Necrosis Factor Alpha (TNF-α) vs Baseline0.240 (0.122 to 1.207)0.270 (0.175 to 0.320)0.270 (0.110 to 0.930)
Statistical analysis
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = <0.001 (Hochberg adjustment may be used.) · Median difference (net): 4.34 · 95% CI 1.7 to 38.0
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = <0.001 (Hochberg adjustment may be used.) · Median difference (net): 3.29 · 95% CI 1.5 to 11.25
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = <0.05 (Hochberg adjustment may be used.) · Median difference (net): 0.4 · 95% CI 0.1 to 0.7
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = 0.052 (Hochberg adjustment may be used.) · Median difference (net): 0.24 · 95% CI -0.01 to 0.96
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = 0.055 (Hochberg adjustment may be used.) · Median difference (net): 0.39 · 95% CI -0.03 to 4.61
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = 0.06 · Median difference (net): 0.54 · 95% CI -0.06 to 1.96Hochberg adjustment may be used.
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = 0.420 (Hochberg adjustment may be used.) · Median difference (net): 0.73 · 95% CI -1.63 to 1.62
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = 0.733 (Hochberg adjustment may be used.) · Median difference (net): -0.39 · 95% CI -1.315 to 1.31
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = 0.010 (Hochberg adjustment may be used.) · Median difference (net): 0.12 · 95% CI 0.04 to 0.21
  • Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Paired samples Wilcoxon rank sum test · p = 0.014 (Hochberg adjustment may be used.) · Median difference (net): 0.10 · 95% CI 0.04 to 0.40
SecondaryChanges in the Immune Parameters Obtained From Biopsies

All evaluable participants will have determinations of many immune parameters at baseline, 3 months, and 6 months. The changes in the parameters obtained from biopsies will be obtained from baseline vs. a single second biopsy at 6 months. Comparisons of the paired values will be performed using a Wilcoxon signed rank test, and a Hochberg adjustment may be used.

Time frame:
baseline, 3 months, and 6 months

Results for this outcome have not been posted.

SecondaryDisease Free Survival (DFS)

A DFS curve will be created using the Kaplan-Meier method based on all participants considered to be evaluable based on having received protocol treatment. DFS survival is defined as the time from the start of treatment until disease recurrence or death. Recurrence is suspected and/or determined by urine cytology and/or cystoscopic exam and then confirmed pathologically after a bladder biopsy or transurethral resection of bladder tumor (TURBT).

Time frame:
Assessed from start of therapy to disease recurrence or last follow up; up to 1 year.
Reported as:
Median · Weeks
Disease Free Survival (DFS)
WeeksRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
Disease Free Survival (DFS)12.8 (12.3 to NA)50.1 (12.3 to NA)13.2 (12.28 to NA)
Statistical analysis
  • Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg · Kaplan-Meier product-limit estimates · Kaplan-meier product-limit: 13.2 · 97.5% CI 2.5 to 97.5
Other pre-specifiedNumber of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
Through study completion, an average of 315 days.
Reported as:
Count of participants · Participants
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
ParticipantsRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)123
Other pre-specifiedMaximum Tolerated Dose (MTD) of Durvalumab

The MTD will be identified based on being the dose level at which 0 or 1 participants in 6 has a dose-limiting toxicity (DLT). A DLT will be defined as any Grade 3 or higher toxicity that occurs during the initial 6-week period the subject is on treatment (i.e., the DLT evaluation period). Grade 3 is severe, grade 4 is life-threatening and grade 5 is death related to adverse event.

Time frame:
6 weeks
Reported as:
Number · Mg
Maximum Tolerated Dose (MTD) of Durvalumab
MgAll Participants
Maximum Tolerated Dose (MTD) of Durvalumab1500
Other pre-specifiedMaximum Tolerated Dose (MTD) of Vicineum

The MTD will be identified based on being the dose level at which 0 or 1 participants in 6 has a dose-limiting toxicity (DLT). A DLT will be defined as any Grade 3 or higher toxicity that occurs during the initial 6-week period the subject is on treatment (i.e., the DLT evaluation period). Grade 3 is severe, grade 4 is life-threatening and grade 5 is death related to adverse event.

Time frame:
6 weeks
Reported as:
Number · Mg
Maximum Tolerated Dose (MTD) of Vicineum
MgAll Participants
Maximum Tolerated Dose (MTD) of Vicineum30
Other pre-specifiedDose-Limiting Toxicity (DLT)

A DLT will be defined as any Grade 3 or higher toxicity that occurs during the initial 6-week period the subject is on treatment (i.e., the DLT evaluation period). Grade 3 is severe, grade 4 is life-threatening and grade 5 is death related to adverse event.

Time frame:
6 weeks
Reported as:
Number · percentage of participants
Dose-Limiting Toxicity (DLT)
percentage of participantsRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
Grade 333.30
Grade 400
Grade 500

Adverse events

Collected over Through study completion, an average of 315 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0/12 (0%)4/12 (33.3%)12/12 (100%)
Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0/3 (0%)0/3 (0%)3/3 (100%)
Total Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg0/15 (0%)4/15 (26.7%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
Bladder infectionInfections and infestations1/120/31/15
HematuriaRenal and urinary disorders1/120/31/15
HyponatremiaMetabolism and nutrition disorders1/120/31/15
Thromboembolic eventVascular disorders1/120/31/15
Most frequent other events
Showing 10 of 83
Most frequent other events
EventRun-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg
NauseaGastrointestinal disorders1/123/34/15
Creatinine increasedInvestigations2/122/34/15
FatigueGeneral disorders2/122/34/15
HematuriaRenal and urinary disorders8/120/38/15
PruritusSkin and subcutaneous tissue disorders5/120/35/15
Urinary frequencyRenal and urinary disorders5/120/35/15
Urinary tract infectionInfections and infestations5/120/35/15
ConstipationGastrointestinal disorders2/121/33/15
DiarrheaGastrointestinal disorders4/120/34/15
DizzinessNervous system disorders0/121/31/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal
<=18 years000
Between 18 and 65 years213
>=65 years10212
Age, Continuous
Age, Continuous(years)Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal
Mean72 ± 872 ± 1072 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal
Female101
Male11314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal
Hispanic or Latino000
Not Hispanic or Latino12315
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White12214
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgExpansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mgTotal
United States12315
07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · May 22, 2025
  • Informed consent form · Feb 21, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).

Supporting information: Study protocol, Sap, Icf

09

Registry details

Key details

Study ID
NCT03258593
Lead sponsor
National Cancer Institute (NCI)
Responsible party
Raju Chelluri (Principal Investigator, National Cancer Institute (NCI)) — Principal investigator
First posted
Aug 23, 2017
Start date
Jun 7, 2018
Primary completion
Aug 1, 2022
Completion
Oct 17, 2022
Results posted
Oct 26, 2023
Last update
Aug 25, 2026

Study contacts

Raju Chelluri, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Urinary Bladder Neoplasms→

Other studies from this sponsor

National Cancer Institute (NCI)

Start the discussion